Clinical trials
Completed Observational Food Hypersensitivity trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 51 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Central Hospital, Nancy, France | 2 |
| Federico II University | 2 |
| Mahidol University | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Niguarda Hospital | 2 |
| Royal Brompton & Harefield NHS Foundation Trust | 2 |
| University Hospital, Montpellier | 2 |
| Arkansas Children's Hospital Research Institute | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Bandim Health Project | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Food Hypersensitivity | 51 |
| Hypersensitivity | 15 |
| Asthma | 10 |
| Dermatitis, Atopic | 9 |
| Peanut Hypersensitivity | 5 |
| Rhinitis, Allergic | 5 |
| Milk Hypersensitivity | 4 |
| Anaphylaxis | 3 |
| Rhinitis | 3 |
| Eczema | 2 |
Trials
Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.